AC Immune
Latest round
- Series E
Last raised
- May 2016
Total raised
- $44M
Investors
- 3
About AC Immune
Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA specializes in innovative therapies for neurodegenerative diseases. The CEO, Andrea Pfeifer, has guided the firm since its inception, contributing to its focus on addressing the challenges posed by proteinopathies associated with neurodegeneration.AC Immune SA specializes in precision medicine aimed at treating neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and certain rare indications. The company's core product offerings include a diverse pipeline of clinical and preclinical candidates, which encompass active immunotherapies, antibodies, small molecule drugs, and diagnostic agents. These products are designed to target specific proteinopathies associated with neurodegeneration, with a focus on detecting and clearing misfolded proteins that contribute to these conditions. By employing advanced technology platforms like Morphomer® and Supraantigen®, AC Immune aims to develop innovative therapies tailored to the unique biological profiles of patients.25 mn for the same year. The company’s revenue model largely revolves around partnerships and collaborations with major pharmaceutical companies, which may involve licensing agreements and joint ventures for the development of therapeutics and diagnostics. These collaborations facilitate the sharing of resources and expertise, allowing AC Immune to advance its product offerings while minimizing the financial burden associated with independent development. Transactions typically encompass upfront payments, milestone payments tied to specific development achievements, and royalties on product sales once they reach the market. The company is focused on developing new products targeting neurodegenerative diseases, with particular emphasis on innovative therapies. AC Immune aims to expand into North America, Europe, and Asia, where neurodegenerative diseases are prevalent, further solidifying its market presence. With a clear strategy for product launches and market expansion, AC Immune is poised for continued growth.
Who invested in AC Immune
3 investors across 1 round
See all investors in AC Immune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series E
May 9, 2016
Amount
$44M
Investors
Questions about AC Immune
Who invested in AC Immune?
AC Immune has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AC Immune raised?
AC Immune has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AC Immune last raise money?
AC Immune's most recent round on record is a Series E, in May 2016.
What does AC Immune do?
Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA specializes in innovative therapies for neurodegenerative diseases.
Where is AC Immune headquartered?
AC Immune is headquartered in Lausanne, Switzerland.
Which VCs invest in companies like AC Immune?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at AC Immune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series E
Raising like AC Immune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.